title: Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
abstract: OBJECTIVE
  The Gynecologic Oncology Group (GOG) has studied a number of drugs to determine their activity in patients with previously treated squamous and nonsquamous cancer arising in the uterine cervix. A Phase II study with intravenous vinorelbine was initiated for this purpose in patients with Stage IVB, recurrent, or persistent nonsquamous carcinomas who had received one prior chemotherapy or were not eligible for other studies.
  
  
  METHODS
  Eligible patients had to have measurable disease, GOG performance status of 0-2 and adequate bone marrow, liver, and renal function. The treatment consisted of vinorelbine 30 mg/m(2) on days 1 and 8, repeated every 21 days. Tumor measurements and toxicities were recorded every treatment cycle.
  
  
  RESULTS
  Thirty patients were enrolled with 28 patients deemed eligible and evaluable. Only two confirmed partial responses (7.1%) were noted. Neutropenia was the most common toxicity with 9 of 28 (32%) experiencing either grade 3 or 4 changes. Anemia was severe in seven. Neuropathy was more than mild in three patients. Severe events, such as fatigue, hypertension, or pulmonary changes attributed to drug administration, occurred only in one or two instances.
  
  
  CONCLUSIONS
  With the dose schedule and assessment criteria employed, vinorelbine had only minimal activity in nonsquamous cancer of the cervix.
authors.affiliation: Department of Medicine, Kaplan Cancer Center, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA. muggif01@gcrc.med.nyu.edu
authors.forename: Franco M
authors.initials: FM
authors.lastname: Muggia
authors.forename: John A
authors.initials: JA
authors.lastname: Blessing
authors.forename: Steven
authors.initials: S
authors.lastname: Waggoner
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Berek
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.forename: Joel
authors.initials: J
authors.lastname: Sorosky
authors.forename: Michael L
authors.initials: ML
authors.lastname: Pearl
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine